comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 18:42:48 - browse：8

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Study: Why relieving medical debt did not improve financial outcomes

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

My daughter's legacy lives on through her writing, phage therapy

Teladoc has a new CEO, but challenges remain the same

Readers respond to H5N1 and livestock movements, and more

Coercive sterilizations revealed by STAT prompt outrage

Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

comprehensive

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

The system is set up to fail children with medical complexity

Medical leaders decry Supreme Court decision on affirmative action

How faith leaders like me can help address America's obesity epidemic

Trump demands the U.S. pay no more for drugs than other countries … again

Glen Campbell's doctor discusses his public struggle with Alzheimer's

The cancer drug shortage isn’t new — and neither are the solutions

California wildfire smoke linked to 52,000 early deaths, study says

State Dept. review finds Biden bears some blame for Afghanistan failures

Glen Campbell's doctor discusses his public struggle with Alzheimer's

focus

Criminal prosecution for violating HIPAA: an emerging threat

Solving academic medical centers' existential crisis

Military medical care influenced by rank and race, new study finds

Case highlights the risks of experimental stem cell therapy

Teladoc has a new CEO, but challenges remain the same

Coercive sterilizations revealed by STAT prompt outrage

focus

hotspot

focus

explore